| Fidel Gerardo Garcia, DNAP | |
|
8700 Beverly Blvd, West Hollywood, CA 90048-1804 | |
| (310) 423-2700 | |
| Not Available |
| Full Name | Fidel Gerardo Garcia |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 3 Years |
| Location | 8700 Beverly Blvd, West Hollywood, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1689243214 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 95001559 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of California Davis Medical Center | Sacramento, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Regents Of The Univ Of Ca | 3375456619 | 1346 |
News Archive
An attack on glioblastoma brain tumor cells that uses a modified poliovirus is showing encouraging results in an early study to establish the proper dose level, researchers at Duke Cancer Institute report.
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with DiNonA Inc. for the development, manufacturing and marketing of Leukotuximab, an anti JL-1 antibody for acute leukemia (AL), including acute myelocytic leukemia (AML) and acute lymphoblastic leukemia (ALL), in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and the Middle East (excluding Cyprus, Egypt, Israel and Turkey).
Horizon Pharma, Inc., a late-stage biopharmaceutical company focused on the development and commercialization of innovative medicines for pain-related diseases and inflammation, today announced that its New Drug Application (NDA) for DUEXA®, a proprietary tablet formulation containing a fixed-dose combination of ibuprofen and high-dose famotidine, was accepted by the U.S. Food and Drug Administration (FDA) for review.
One of the reasons why cancer develops is because regulatory cells inhibit the body's immune defense. Researchers under the helm of the Technical University of Munich have discovered a mechanism for identifying regulatory cells in tumor tissue that suppress an immune response.
Dyadic International, Inc. announced today an agreement to resolve the consolidated stockholder class action lawsuit against Dyadic and certain of its current and former officers and directors which was initially filed in October 2007.
› Verified 2 days ago
| Entity Name | Regents Of The Univ Of Ca |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013906973 PECOS PAC ID: 3375456619 Enrollment ID: O20031111000892 |
News Archive
An attack on glioblastoma brain tumor cells that uses a modified poliovirus is showing encouraging results in an early study to establish the proper dose level, researchers at Duke Cancer Institute report.
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with DiNonA Inc. for the development, manufacturing and marketing of Leukotuximab, an anti JL-1 antibody for acute leukemia (AL), including acute myelocytic leukemia (AML) and acute lymphoblastic leukemia (ALL), in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and the Middle East (excluding Cyprus, Egypt, Israel and Turkey).
Horizon Pharma, Inc., a late-stage biopharmaceutical company focused on the development and commercialization of innovative medicines for pain-related diseases and inflammation, today announced that its New Drug Application (NDA) for DUEXA®, a proprietary tablet formulation containing a fixed-dose combination of ibuprofen and high-dose famotidine, was accepted by the U.S. Food and Drug Administration (FDA) for review.
One of the reasons why cancer develops is because regulatory cells inhibit the body's immune defense. Researchers under the helm of the Technical University of Munich have discovered a mechanism for identifying regulatory cells in tumor tissue that suppress an immune response.
Dyadic International, Inc. announced today an agreement to resolve the consolidated stockholder class action lawsuit against Dyadic and certain of its current and former officers and directors which was initially filed in October 2007.
› Verified 2 days ago
| Entity Name | Anesthesia Services Of San Joaquin Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366778227 PECOS PAC ID: 4082754056 Enrollment ID: O20091223000174 |
News Archive
An attack on glioblastoma brain tumor cells that uses a modified poliovirus is showing encouraging results in an early study to establish the proper dose level, researchers at Duke Cancer Institute report.
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with DiNonA Inc. for the development, manufacturing and marketing of Leukotuximab, an anti JL-1 antibody for acute leukemia (AL), including acute myelocytic leukemia (AML) and acute lymphoblastic leukemia (ALL), in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and the Middle East (excluding Cyprus, Egypt, Israel and Turkey).
Horizon Pharma, Inc., a late-stage biopharmaceutical company focused on the development and commercialization of innovative medicines for pain-related diseases and inflammation, today announced that its New Drug Application (NDA) for DUEXA®, a proprietary tablet formulation containing a fixed-dose combination of ibuprofen and high-dose famotidine, was accepted by the U.S. Food and Drug Administration (FDA) for review.
One of the reasons why cancer develops is because regulatory cells inhibit the body's immune defense. Researchers under the helm of the Technical University of Munich have discovered a mechanism for identifying regulatory cells in tumor tissue that suppress an immune response.
Dyadic International, Inc. announced today an agreement to resolve the consolidated stockholder class action lawsuit against Dyadic and certain of its current and former officers and directors which was initially filed in October 2007.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Fidel Gerardo Garcia, DNAP 8700 Beverly Blvd Ste Sb-290, West Hollywood, CA 90048-1804 Ph: (310) 423-1447 | Fidel Gerardo Garcia, DNAP 8700 Beverly Blvd, West Hollywood, CA 90048-1804 Ph: (310) 423-2700 |
News Archive
An attack on glioblastoma brain tumor cells that uses a modified poliovirus is showing encouraging results in an early study to establish the proper dose level, researchers at Duke Cancer Institute report.
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with DiNonA Inc. for the development, manufacturing and marketing of Leukotuximab, an anti JL-1 antibody for acute leukemia (AL), including acute myelocytic leukemia (AML) and acute lymphoblastic leukemia (ALL), in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and the Middle East (excluding Cyprus, Egypt, Israel and Turkey).
Horizon Pharma, Inc., a late-stage biopharmaceutical company focused on the development and commercialization of innovative medicines for pain-related diseases and inflammation, today announced that its New Drug Application (NDA) for DUEXA®, a proprietary tablet formulation containing a fixed-dose combination of ibuprofen and high-dose famotidine, was accepted by the U.S. Food and Drug Administration (FDA) for review.
One of the reasons why cancer develops is because regulatory cells inhibit the body's immune defense. Researchers under the helm of the Technical University of Munich have discovered a mechanism for identifying regulatory cells in tumor tissue that suppress an immune response.
Dyadic International, Inc. announced today an agreement to resolve the consolidated stockholder class action lawsuit against Dyadic and certain of its current and former officers and directors which was initially filed in October 2007.
› Verified 2 days ago
Dr. Nicole Christine Creef, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 8700 Beverly Blvd, West Hollywood, CA 90048 Phone: 310-423-3277 | |
Ngoc-thao Nguyen, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 8700 Beverly Blvd # 2900a, West Hollywood, CA 90048 Phone: 310-423-3277 | |
Brianna Koty, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 8700 Beverly Blvd # Sb290, West Hollywood, CA 90048 Phone: 310-423-1447 Fax: 310-423-0387 | |
Billy F Messer Jr., CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 8700 Beverly Blvd, West Hollywood, CA 90048 Phone: 310-423-1447 Fax: 310-423-0387 | |
Elisha Bilsborough, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 8700 Beverly Blvd, West Hollywood, CA 90048 Phone: 530-798-3270 | |
Zhi Jing, Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 8700 Beverly Blvd # Sb290, West Hollywood, CA 90048 Phone: 310-423-1447 Fax: 310-423-0987 | |
Dr. Michelle Horton, DNP, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 8700 Beverly Blvd, West Hollywood, CA 90048 Phone: 800-233-2771 |